Drug therapy for coronary heart disease: The Sheffield table (multiple letters) [2]

Lancet

Volumn 350, Issue 9094, 1997, Pages 1852-1854

  Wallis, E J ^a   Ramsay, L E ^a   Jackson, P R ^a   Yeo, W W ^a   Williamson, R ^a   Vallance, P ^a   Martin, J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; HYPOCHOLESTEROLEMIC AGENT;

BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; COMPUTER ANALYSIS; CORONARY RISK; COST BENEFIT ANALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; CORONARY ARTERY DISEASE; FEMALE; HYPERCHOLESTEROLEMIA; MALE; NOTE; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0031581417     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63671-9     Document Type: Letter

References (5)

1. AF Jones Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines Lancet 30 1997 1174 1175
2. LE Ramsay IQ Haq PR Jackson WW Yeo DM Pickin JN Payne Targeting lipidlowering drug therapy for primary prevention of coronary disease: an updated Sheffield table Lancet 348 1996 387 388
3. IU Haq LE Ramsay DM Pickin WW Yeo PR Jackson JN Payne Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 91 1996 399 413
4. WB Kannel Lipids, diabetes, and coronary heart disease: insights from the Framingham Study Am Heart J 110 1985 1100 1107
5. IU Haq PR Jackson WW Yeo LE Ramsay A comparison of methods for targeting CHD risk for primary prevention Heart 77 suppl 1 1997 36